Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. ...
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02843074
- Locations
- 🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT02719613
- Locations
- 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵Local Institution - 0048, Koto-ku, Tokyo, Japan
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT02718833
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Newton-Wellesley Hospital, Newton, Massachusetts, United States
Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hearn Jay Cho
- Target Recruit Count
- 15
- Registration Number
- NCT02655458
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 117
- Registration Number
- NCT02654132
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT02612779
- Locations
- 🇺🇸
Bay Hematology Oncology, Easton, Maryland, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Sundar Jagannath
- Registration Number
- NCT02541643
- Locations
- 🇺🇸
Icahn School.of Medicine at Mount Sinai, New York, New York, United States
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 564
- Registration Number
- NCT02495922
- Locations
- 🇩🇪
Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II, Villingen-Schwenningen, Germany
🇩🇪Rems-Murr-Klinikum gGmbH Winnenden, Winnenden, Germany
🇩🇪Studienzentrum Aschaffenburg, Aschaffenburg, Germany
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
- Conditions
- Interventions
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02375555
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.